What is the likelihood of Stevens-Johnson syndrome occurring with lamotrigine in a patient who previously experienced Stevens-Johnson syndrome with terbinafine (Lamisil)?

Risk of Stevens-Johnson Syndrome with Lamotrigine After Prior SJS from Terbinafine

A patient who developed Stevens-Johnson syndrome with terbinafine (Lamisil) should generally be considered at higher risk for SJS with lamotrigine, though the absolute risk remains low and cross-reactivity between these structurally unrelated drugs is not well-established.

Understanding the Risk Profile

The baseline risk of lamotrigine-induced SJS/TEN in the general population is approximately 0.04% (4 in 10,000 patients) 1, though some older estimates suggest it may be as high as 1 in 1,000 2. However, having a prior history of SJS to any drug fundamentally changes the risk calculation, even when the culprit drugs are structurally dissimilar.

Key Mechanistic Considerations

• T-cell mediated hypersensitivity: Both terbinafine-induced and lamotrigine-induced SJS are delayed-type (Type IV) hypersensitivity reactions mediated by drug-specific T lymphocytes 3

• No structural cross-reactivity expected: Terbinafine (an antifungal) and lamotrigine (a phenyltriazine antiepileptic) are chemically unrelated, unlike the documented cross-reactivity seen among aromatic anticonvulsants (carbamazepine, phenytoin, phenobarbital) 3

• Individual susceptibility: A history of SJS suggests an underlying predisposition to severe cutaneous adverse reactions, potentially related to immune dysregulation or genetic factors (HLA subtypes), even if the specific genetic markers differ between drugs

Clinical Decision Framework

Absolute Contraindications to Lamotrigine

• Prior SJS/TEN specifically from lamotrigine or structurally related aromatic anticonvulsants
• Known HLA-B15:02 (in Chinese/Southeast Asian patients), HLA-B31:01 (Japanese), or HLA-B*44:03 (Korean) genotypes 4

Relative Contraindications (Your Patient's Scenario)

• Prior SJS/TEN from an unrelated drug (terbinafine)
• This represents a significantly elevated baseline risk compared to the general population, though precise quantification is not available in the literature

If Lamotrigine Must Be Used

The decision requires:

1. Documented medical necessity where therapeutic alternatives are inadequate

2. Informed consent with explicit discussion of elevated SJS risk

3. Genetic testing: Consider HLA typing before initiation 4

4. Strict dosing protocol:

   • Start at 12.5-25 mg daily (lower than standard)
   • Titrate more slowly than manufacturer recommendations
   • Avoid concomitant valproic acid, which increases lamotrigine levels and SJS risk 5, 2, 6

5. Intensive monitoring during weeks 1-8: Most cases occur within the first month, with peak risk in weeks 2-8 5, 6

Warning Signs Requiring Immediate Discontinuation

• Fever (often precedes rash by 1-2 days)
• Mucosal involvement (oral erosions, conjunctivitis)
• Targetoid lesions or any blistering
• Painful skin
• Flu-like prodrome with rash

Critical Pitfalls to Avoid

Do not:

• Assume safety because the prior SJS was from a different drug class
• Continue lamotrigine if any suspicious rash develops—immediate discontinuation is mandatory 5, 7
• Use rapid dose escalation, which dramatically increases risk 5
• Combine with valproic acid in this high-risk patient (increases lamotrigine levels 2-fold and SJS risk) 5, 2

Do:

• Document the prior SJS episode thoroughly, including timing, severity, and causative agent
• Consider alternative medications first (levetiracetam, topiramate for seizures; lithium, quetiapine for mood disorders)
• Educate the patient to stop lamotrigine immediately and seek emergency care for any rash, fever, or mucosal symptoms

Evidence Limitations

The 2016 UK guidelines on SJS/TEN management 3 note that diagnostic testing (patch tests, lymphocyte transformation tests) for drug causality in SJS/TEN has poor sensitivity (9-62% for patch tests, 21-55% for LTT depending on the drug) and cannot reliably predict cross-reactivity to other agents. There is no validated test to determine if your patient will react to lamotrigine based on their terbinafine history.

The emerging trend of lamotrigine-associated SJS, particularly with off-label psychiatric use, has increased from 6.7% to 40% of SJS cases in some burn centers between 2015-2022 6, making heightened vigilance essential.

In practical terms: This patient's prior SJS history makes lamotrigine a higher-risk choice that should only be pursued if therapeutic alternatives are truly inadequate, with meticulous informed consent, genetic screening consideration, ultra-slow titration, and intensive early monitoring.